Business Description
Dimerix Ltd
ISIN : AU000000DXB7
Description
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.37 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 0.83 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -20.5 | |||||
3-Year EPS without NRI Growth Rate | -17.3 | |||||
3-Year FCF Growth Rate | -13 | |||||
3-Year Book Growth Rate | -27.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.84 | |||||
Quick Ratio | 4.84 | |||||
Cash Ratio | 4.76 | |||||
Days Sales Outstanding | 1169.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.5 | |||||
Shareholder Yield % | -1.72 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -14984.21 | |||||
Net Margin % | -8170.68 | |||||
FCF Margin % | 511.24 | |||||
ROE % | -260.18 | |||||
ROA % | -83.17 | |||||
ROIC % | -711.16 | |||||
ROC (Joel Greenblatt) % | -239148 | |||||
ROCE % | -261.49 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 137.5 | |||||
EV-to-EBIT | -11.09 | |||||
EV-to-EBITDA | -11.09 | |||||
EV-to-Revenue | 1661.77 | |||||
EV-to-FCF | 314.84 | |||||
Earnings Yield (Greenblatt) % | -9.02 | |||||
FCF Yield % | 0.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SBMJF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dimerix Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.089 | ||
EPS (TTM) ($) | -0.02 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 0.002 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 0.002 - 0.002 | ||
Shares Outstanding (Mil) | 549.74 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Dimerix Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Dimerix Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Dimerix Ltd Frequently Asked Questions
What is Dimerix Ltd(SBMJF)'s stock price today?
The current price of SBMJF is $0.00. The 52 week high of SBMJF is $0.00 and 52 week low is $0.00.
When is next earnings date of Dimerix Ltd(SBMJF)?
The next earnings date of Dimerix Ltd(SBMJF) is .
Does Dimerix Ltd(SBMJF) pay dividends? If so, how much?
Dimerix Ltd(SBMJF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |